The deal gives Taiyo an enterprise value of $1.3 billion and is expected to be accretive to GAAP earnings within four quarters after closing, Teva (TEVA.TA Taiyo is the third largest generic pharmaceutical company in Japan with sales of $530 million in...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Teva to buy 57 percent of Taiyo for $460 million
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account